within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M02A_TopicalProductsForJointAndMuscularPain.M02AA06_Etofenamate;

model Etofenamate
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 4.861111111111111e-08,
    adminDuration = 600,
    adminMass = 300 / 1000000,
    adminCount = 1,
    Vd = 0.02,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Etofenamate</td></tr><tr><td>ATC code:</td><td>M02AA06</td></tr><td>route:</td><td>topical</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>20</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.175</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Etofenamate is a nonsteroidal anti-inflammatory drug (NSAID) in the class of anthranilic acid derivatives. It is used topically for the treatment of musculoskeletal pain and inflammation, such as in osteoarthritis, sports injuries, and soft tissue rheumatism. Etofenamate is commonly available in gel or cream form for dermal application. It is approved and in clinical use in several European and Asian countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers after topical administration of etofenamate gel 5%, assessed by systemic absorption and plasma pharmacokinetics.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M02AA06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Etofenamate;
